[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-patients-undergoing-minimally-invasive-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-patients-undergoing-minimally-invasive-gastrectomy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100608461","peri-habilitation-for-patients-with-gastric-cancer-100608461",false,"NCT07201857","Peri-habilitation for Patients With Gastric Cancer","Peri-habilitation to Enhance Treatment Outcomes and Postoperative Recovery in Patients With Gastric Cancer","Inclusion Criteria:\n\n* Patients aged 65 years or older who have been diagnosed with gastric cancer and are scheduled to undergo surgical treatment or chemotherapy.\n\nExclusion Criteria:\n\n* Patients with severe conditions who are unable to undergo the intervention prior to surgical treatment or chemotherapy.\n* Patients with physical (e.g., musculoskeletal) or mental disorders that make participation in or continuation of the program impossible.\n* Patients judged to be at risk of additional physical burden from the intervention.","ALL","65 Years","90 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and nutrition intervention for about three weeks after hospital discharge, and by analyzing its effects on the prevention of postoperative complications and recovery.",[27,28,29,30,31],"Gastric Cancer (Diagnosis)","Gastric Cancer Patient","Gastric Cancer Patients Undergoing Gastrectomy","Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy","Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy",[33,34,35,36],"peri-habilitation","gastric cancer","postoperative recovery","exercise intervention","NOT_YET_RECRUITING","2025-09-23",{"date":40,"type":41},"2025-10-01","ACTUAL",{"date":43,"type":21},"2025-10-15",{"date":45,"type":21},"2026-12-31",{"name":47,"class":48},"Korea University Anam Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100568286","application-of-a-new-surgical-technique-in-proximal-gastrectomy-a-prospective-multicenter-randomized-controlled-study-100568286","NCT06679244","Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study","Application of Hao's Esophagogastrostomy by Fissure Technique: a Prospective, Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. 18 years old ≤ 80 years old;\n2. The primary tumor lesion is located in the upper part of the stomach or the esophagogastric junction (Siewert II or III), and it is expected that R0 surgical results can be obtained by performing proximal gastrectomy and D2 dissection；\n3. The primary lesion was diagnosed as adenocarcinoma through endoscopic biopsy and histopathological examination;\n4. If it is upper gastric adenocarcinoma, the clinical TNM staging based on imaging needs to be cT1N0M0. If it is ductal gastric junction adenocarcinoma, it needs to be cT1-3N0-1M0, and clinical imaging judgment shows no distant gastric lymph node metastasis；\n5. Expected survival exceeds 6 months;\n6. No history of upper abdominal surgery (excluding laparoscopic cholecystectomy);\n7. No chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. were performed before surgery;\n8. Preoperative ECOG (Eastern Cooperative Oncology Group) physical status score 0\u002F1;\n9. Preoperative ASA (American Society of Anesthesiologists) grading I-III ;\n10. Good function of important organs;\n11. Sign the patient's informed consent form\n\nExclusion Criteria:\n\n1. Preoperative imaging examination suggests the fusion of enlarged lymph nodes (maximum diameter ≥ 3cm) in the area;\n2. Pregnant and lactating women;\n3. Suffering from other malignant tumors within 5 years;\n4. Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment;\n5. Serious mental illness;\n6. Severe respiratory diseases, FEV1\\\u003C50% of the expected value;\n7. Severe liver and kidney dysfunction;\n8. History of unstable angina or heart attack within 6 months;\n9. History of cerebral infarction or cerebral hemorrhage within 6 months, excluding old intracavitary infarction;\n10. Apply systemic corticosteroid therapy within one month;\n11. Patients with complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery;\n12. The patient has participated or is currently participating in other clinical studies (within 6 months)","18 Years","80 Years",{"count":60,"type":21},52,[24],"This is a prospective study using a multicenter, randomized, controlled, open label, and efficacy validated approach.At present, there is no universally recognized optimal method for gastrointestinal reconstruction after proximal gastrectomy in the surgical treatment of gastric cancer.Author's team has proposed an innovative method named Hao's Esophagogastrostomay by Fisture Technique (HEFT).By adding anti reflux structures such as \"false gastric fundus\" and \"false cardia\" to the anastomosis of the residual stomach of the esophagus, not only can the purpose of anti reflux be achieved, but also the normal physiological channel can be maintained, it can fully utilize residual stomach function and reduce the difficulty of surgery.Through retrospective research, our single center has confirmed that HEFT is safe and feasible.On this basis, this study will compare the nutritional status, short- and medium- to long-term safety after laparoscopic HEFT and double-tract reconstruction , in order to evaluate and discover more reasonable digestive tract reconstruction methods after proximal gastrectomy, and to promote the development and popularization of minimally treatment technology for gastric cancer.\n\nThis study was jointly conducted by Shanghai-level hospitals (Huashan Hospital ,Shanghai Cancer Center, and Ruijin Hospital), with Huashan Hospital as the leading unit. This study will recruit 52 patients, with 26 patients in the experimental group and 26 patients in the control group. Using a central dynamic randomization method based on minimization, patients are assigned to groups in a 1:1 ratio. Based on the different anastomotic methods used in proximal gastrectomy, patients are divided into a HEFT group (experimental group) and a double-tract reconstruction group (control group).Plan to collect cases for 2 years, and follow up for another year after the last case is enrolled.\n\nThe primary endpoint of the study was the body weight loss (BWL) rate at 1 year after surgery. Secondary endpoints: Effect evaluation indicators: hemoglobin level at 1 year after surgery; Serum albumin level at 1 year after surgery; The incidence of anastomotic stenosis 1 year after surgery; Incidence of reflux esophagitis at 1 year after surgery. Evaluation of short-term surgical safety (duration: 7 days): operation time, intraoperative bleeding, anastomotic leakage, pancreatic leakage, and incidence of abdominal infection; Evaluation of medium- and long-term safety after surgery (duration: 36 months): overall survival rate at 3 years after surgery; disease-free survival rate at 3 years after surgery.",[30],[65,66,67],"proximal gastrectomy","totally laparoscopic gastrectomy","fissure technique","RECRUITING","2025-07-20",{"date":71,"type":41},"2025-07-22",{"date":73,"type":41},"2024-12-04",{"date":75,"type":21},"2029-06",{"name":77,"class":48},"Huashan Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100587933","clinical-study-of-double-endoscopic-combined-with-minimally-invasive-treatment-for-early-gastric-cancer-at-clinical-stage-t1b-100587933","NCT06934824","Clinical Study of Double-Endoscopic Combined With Minimally Invasive Treatment for Early Gastric Cancer at Clinical Stage T1b","Inclusion Criteria:\n\n1. Age 18-70 years old;\n2. Endoscopic pathological diagnosis: adenocarcinoma;\n3. Enhanced abdominal CT combined with endoscopic ultrasound clinical staging: T1bN0-1M0.\n4. Has not received other treatment;\n5. No other serious comorbidities;\n6. Agree to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. History of previous abdominal surgery\n3. History of other previous malignancies\n4. Can patients with severe heart, lung, brain diseases tolerate surgical treatment","70 Years",{"count":86,"type":21},60,[24],"For patients diagnosed with early gastric cancer involving submucosal invasion, super-ESD indications, or lymph node metastasis, a combination of preoperative endoscopic ultrasound and abdominal contrast-enhanced CT was utilized to ascertain the depth of tumor invasion and to identify any suspicious metastatic lymph nodes in the vicinity of the stomach. Subsequently, a local full-thickness resection, coupled with or followed by individualized precise lymph node dissection, was conducted to fulfill the following objectives: ① To investigate the safety, feasibility, and efficacy of local resection for patients meeting super-ESD criteria; ② To offer a clinical foundation for the individualized and precise lymph node dissection treatment of early gastric cancer.",[30],"2025-04-12",{"date":92,"type":41},"2025-04-18",{"date":94,"type":21},"2025-05-01",{"date":96,"type":21},"2027-01-01",{"name":98,"class":48},"Hebei Medical University"]